Details

Autor(en) / Beteiligte

• Graus, Merlijn U.J.E.
• de Hingh, Ignace H.J.T.
• Besselink, Marc G.
• Bruno, Marco J.
• Wilmink, Johanna W.
• de Meijer, Vincent E.
• van Velthuysen, Marie-Louise F.
• Valkenburg-van Iersel, Liselot B.J.
• van der Geest, Lydia G.M.
• de Vos-Geelen, Judith
• Siesling, S.
• van Hoeve, J.C.
• Merkx, M.A.W.
• de Wit, N.J.
• Helsper, C.W.
• Dingemans, I.
• Nagtegaal, I.D.
• van der Schaaf, M.
• van Gils, C.H.
• van Weert, H.C.P.M.
• Verheij, M.

Titel

Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer

Ist Teil von

• HPB (Oxford, England), 2023-10, Vol.25 (10), p.1195-1202

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care. All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Cancer Registry. Patients diagnosed and/or treated in 2020 were compared to 2017–2019. Monthly incidence was calculated. Patient, tumor and treatment characteristics were analyzed and compared using Chi-squared tests. Survival data was analyzed using Kaplan–Meier and Log-rank tests. In total, 11019 patients were assessed. The incidence in quarter (Q)2 of 2020 was comparable with that in Q2 of 2017–2019 (p = 0.804). However, the incidence increased in Q4 of 2020 (p = 0.031), mainly due to a higher incidence of metastatic disease (p = 0.010). Baseline characteristics, surgical resection (15% vs 16%; p = 0.466) and palliative systemic therapy rates (23% vs 24%; p = 0.183) were comparable. In 2020, more surgically treated patients received (neo)adjuvant treatment compared to 2017–2019 (73% vs 67%; p = 0.041). Median overall survival was comparable (3.8 vs 3.8 months; p = 0.065). This nationwide study found a minor impact of the COVID-19 pandemic on pancreatic cancer care and outcome. The Dutch health care system was apparently able to maintain essential care for patients with pancreatic cancer.